Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Artificial Intelligence and Machine Learning in Survival Prediction in Chronic Lymphocytic Leukemia: A Systematic Review of Predictive Modeling Approaches

CLL - 1068

Artificial Intelligence and Machine Learning in Survival Prediction in Chronic Lymphocytic Leukemia: A Systematic Review of Predictive Modeling Approaches

Lakshmi Chandana Velaga

Poster Presenter: Lakshmi Chandana Velaga

Thumbnail for Artificial Intelligence in Chronic Myeloid Leukemia: Assessing the Accuracy and Clinical Utility of Large Language Models

CML - 457

Artificial Intelligence in Chronic Myeloid Leukemia: Assessing the Accuracy and Clinical Utility of Large Language Models

Berkha Rani

Poster Presenter: Berkha Rani

Previous 1...6 7 8 9 10 11 12...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Artificial Intelligence in the Diagnosis of Severe Aplastic Anemia: A Systematic Review of Emerging Diagnostic Models

MDS - 098

Artificial Intelligence in the Diagnosis of Severe Aplastic Anemia: A Systematic Review of Emerging Diagnostic Models

Eman M Nagiub

Poster Presenter: Eman M Nagiub

$Thumbnail for Artificial Intelligence, Machine Learning, and Radiomics-Based Prediction Models in Relapsed or Refractory Hodgkin Lymphoma: A Systematic Review$

HL - 1062

Artificial Intelligence, Machine Learning, and Radiomics-Based Prediction Models in Relapsed or Refractory Hodgkin Lymphoma: A Systematic Review

Sai Harsha Yendluri

Poster Presenter: Sai Harsha Yendluri

Thumbnail for Artificial Intelligence-Based Survival Prediction Models in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

AML - 1230

Artificial Intelligence-Based Survival Prediction Models in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Xiaoyi Zhang

Poster Presenter: Xiaoyi Zhang

Thumbnail for ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

CML - 1050

ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Ghayas Issa

Poster Presenter: Ghayas Issa

Thumbnail for Asciminib (ASC) in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Analysis (IA) Efficacy and Safety Results of the Phase 2 ASC2ESCALATE Trial in the Cohort of Newly Diagnosed Patients

CML - 918

Asciminib (ASC) in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Analysis (IA) Efficacy and Safety Results of the Phase 2 ASC2ESCALATE Trial in the Cohort of Newly Diagnosed Patients

Moshe Levy

Poster Presenter: Moshe Levy

Thumbnail for Asciminib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP): A Retrospective Chart Review Study in the US

CML - 692

Asciminib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP): A Retrospective Chart Review Study in the US

Ehab L Atallah

Poster Presenter: Ehab L Atallah

Thumbnail for Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

CML - 913

Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

Ali Turunc

Poster Presenter: Ali Turunc

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors